Last reviewed · How we verify
Atrovent + Bricanyl or Atrovent + Ventoline
This combination pairs an anticholinergic bronchodilator with a beta-2 agonist bronchodilator to relax airway smooth muscle through dual pathways.
This combination pairs an anticholinergic bronchodilator with a beta-2 agonist bronchodilator to relax airway smooth muscle through dual pathways. Used for Chronic obstructive pulmonary disease (COPD), Asthma (acute exacerbation or maintenance therapy).
At a glance
| Generic name | Atrovent + Bricanyl or Atrovent + Ventoline |
|---|---|
| Sponsor | University Hospital, Tours |
| Drug class | Combination bronchodilator (anticholinergic + beta-2 agonist) |
| Target | Muscarinic acetylcholine receptors (M3) and beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Atrovent (ipratropium) blocks muscarinic acetylcholine receptors to prevent bronchoconstriction, while Bricanyl (terbutaline) or Ventoline (albuterol/salbutamol) activates beta-2 adrenergic receptors to promote bronchodilation. Together, they provide complementary mechanisms for rapid and sustained airway opening in obstructive airway disease.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma (acute exacerbation or maintenance therapy)
Common side effects
- Tremor
- Tachycardia
- Headache
- Dry mouth
- Nervousness/anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: